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Abstract
Background: Access to long-lasting insecticidal nets (LLINs) has increased and malaria has decreased globally, but
malaria transmission remains high in parts of sub-Saharan Africa and insecticide resistance threatens current
progress. Eave tubes are a new tool for the targeted delivery of insecticides against mosquitoes attempting to enter
houses. The primary objective of this trial is to test whether screening plus eave tubes (SET) provides protection
against malaria, on top of universal coverage with LLINs in an area of intense pyrethroid resistance. The trial will
also assess acceptability and cost-effectiveness of the intervention.
Methods/design: A two-armed, cluster randomized controlled trial will be conducted to evaluate the effect of SET
on clinical malaria incidence in children living in central Côte d’Ivoire. Forty villages will be selected based on
population size and the proportion of houses suitable for modification with SET. Using restricted randomization,
half the villages will be assigned to the treatment arm (SET + LLINs) and the remainder will be assigned to the
control arm (LLINs only). In both arms, LLINs will be distributed and in the treatment arm, householders will be
offered SET.
Fifty children aged six months to eight years old will be enrolled from randomly selected households in each of the
40 villages. Cohorts will be cleared of malaria parasites at the start of the study and one year after recruitment, and
will be monitored for clinical malaria case incidence by active case detection over two years. Mosquito densities will
be assessed using CDC light traps and human landing catches and a subset of Anopheles mosquitoes will be
examined for parity status and tested for sporozoite infection.
Acceptability of SET will be monitored using surveys and focus groups. Cost-effectiveness analysis will measure the
incremental cost per case averted and per disability-adjusted life year (DALY) averted of adding SET to LLINs.
Economic and financial costs will be estimated from societal and provider perspective using standard economic
evaluation methods.
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Discussion: This study will be the first evaluation of the epidemiological impact of SET. Trial findings will show
whether SET is a viable, cost-effective technology for malaria control in Côte d’Ivoire and possibly elsewhere.
Trial registration: ISRCTN18145556, registered on 01 February 2017 – retrospectively registered.
Keywords: Eave tubes, Screening plus eave tubes, SET, Housing, House screening, Malaria control, Clinical malaria,
LLINs, Cost-effectiveness, Economic evaluation
Background
The incidence of malaria worldwide declined by 41%
between 2000 and 2015 [1, 2]. Malaria vector control
tools, primarily long-lasting insecticidal nets (LLINs) and
indoor residual spraying (IRS), have been instrumental in
reducing the global disease burden [2]. Maintaining and
extending this progress requires innovative, cost-effective
vector control methods to overcome challenges including
remaining areas of high transmission, increasing levels
of insecticide resistance in vector populations, and
operational and financing constraints on LLIN and
IRS [3–8].
Although house modifications to prevent mosquito
entry are not a new malaria control tool [9, 10], there is
recent renewed interest in improved housing - such as re-
placing thatch roofs with metal, screening windows, and
closing eaves (i.e., the gap between the top of the wall and
the roof) - for the purpose of malaria control [11]. An on-
going randomized controlled trial (RCT) in the Gambia is
testing the epidemiological and entomological impact of
replacing thatch roofs with metal, and screening open
eaves, windows and doors, in addition to the current best
practice of LLINs [12]. Another RCT carried out in the
same region found a 22% reduction in the number of mal-
aria vectors (Anopheles gambiae mosquitoes) captured in-
doors, and a 7% reduction in anemia in children living in
houses with screening and closed eaves, compared to un-
modified houses [13]. A recent detailed analysis of survey
data from 21 countries throughout sub-Saharan Africa
found a significant inverse association between “modern”
house traits and reduced malaria prevalence in children,
on par with the protection provided by insecticide treated
bednets [14].
Open eaves, which are found in many traditional
African houses, are a particularly important source of at-
tractive cues for malaria mosquitoes, and represent the
key entry point for An. gambiae in sub-Saharan Africa
[15–18]. It was this aspect of mosquito behavior that mo-
tivated the initial development of eave tubes [19–22]. Eave
tubes provide targeted insecticide treatment and, in com-
bination with “mosquito proofing” of the house (screening
windows, closing eaves and sealing any other cracks or
openings), reduce mosquito entry into the house while
still maintaining airflow through the eaves. Relying on
cues that typically draw malaria mosquitoes into houses,
eave tubes turn the house into what is effectively a “lure
and kill” device.
The eave tube consists of a section of pipe fitted into a
closed eave, with a screened insert that is placed inside the
tube. The insert is treated with an electrostatic coating,
which holds powder formulations of insecticides. This
insecticide delivery method can be highly effective, even
against resistant mosquitoes [23]. Killing mosquitoes as
they attempt to enter houses via the eave tubes offers
potential for community level impact, similar to that ob-
served with insecticide treated bednets, if the coverage of
the technology is high [19]. The screening component,
which physically reduces mosquito entry into the
house, offers passive protection for every person sleep-
ing inside the house, regardless of whether they are
under a bednet.
The aim of the cluster randomized controlled trial
(CRT) presented here is to determine whether screening
plus eave tubes, the SET intervention, provides protection
against malaria, on top of the current best practice of uni-
versal coverage of LLINs (one bednet per two people).
LLINs are the primary tool used for malaria vector control
globally [1] and therefore the trial is designed to reveal
any benefits from SET on top of standard control mea-
sures. The trial will be based in central Côte d’Ivoire,
where there is intense insecticide resistance [24], to evalu-
ate the efficacy, acceptability, and cost-effectiveness of the
intervention in an area where existing vector control tools
may be compromised by resistance.
Study objectives
Epidemiology
Primary objective
To assess whether SET (screening plus eave tubes) and
LLINs (at universal coverage) reduces the incidence of
clinical malaria in children between the ages of
six months and ten years, compared to universal cover-
age of LLINs alone.
Secondary objectives
– Assess whether SET + LLINs reduces the incidence
of malaria infection in children between the ages of
six months and ten years, compared to LLINs alone.
Sternberg et al. BMC Public Health  (2018) 18:894 Page 2 of 13
– Assess whether SET + LLINs reduces the prevalence
of anemia in children between the ages of
six months and five years, compared to LLINs alone.
– Assess whether SET + LLINs is associated with a
rise in symptoms of respiratory infections in
children between the ages of six months and
ten years, compared to LLINs alone.
Entomology
Primary objective
Assess the impact of SET + LLINs on indoor and outdoor
densities of malaria vectors, compared to LLINs alone.
Secondary objectives
– Assess the impact of SET + LLINs on entomological
inoculation rate (EIR; mean number of sporozoite
infective bites/person/year), compared to LLINs
alone.
– Assess the impact of SET + LLINs on parity in the
malaria vector population, compared to LLINs
alone.
– Monitor levels of insecticide resistance in villages
that receive SET + LLINs, compared to villages that
receive LLINs alone.
Social science
Primary objective
Assess end users’ perceptions of and willingness to adopt
SET in the treatment and control arms, and predictors
of those perceptions and actions.
Secondary objectives
– Assess malaria prevention behavior in households
with SET versus LLINs alone, as well as within the
treatment and control arms.
– Assess willingness to maintain SET and identified
key factors that influence willingness to maintain.
– Measure attitudes, emotions, knowledge, and beliefs
relating to malaria and malaria control interventions,
including SET and LLINs.
Economics
Primary objective
Measure the incremental cost-effectiveness of adding
SET to LLINs from the societal and provider perspective
under trial conditions.
Secondary objectives
– Establish the relative contribution to costs of the
distinct programmatic elements (house
modifications, installation of the eave tubes,
treatment and retreatment of the eave tube inserts
with insecticides, and maintenance of the housing
repairs and eave tubes), and identify the inputs that
contribute the most to overall costs.
– Estimate the potential cost of providing SET at
larger scale over an extended period of 3 and 5 years
under operational scenarios.
Methods/design
Study area
The study site is situated in the Gbêkê region in central
Côte d’Ivoire. It is highly malaria endemic with
year-round transmission, peaking during the rainy
season (May through October) [25–27]. Forty candidate
villages have been identified within a 60 km radius
around the town of Bouaké (Fig. 1). Selection criteria for
these candidate villages were: between 100 to 600
houses, at least 80% of houses suitable for installation
of the SET intervention (i.e. roofs made out of metal
sheeting and walls made out of concrete or brick), and
villages at least 2 km from any other candidate study
village.
Participant recruitment
Community consent to participate in the study will be
obtained through meetings with village leaders and in-
habitants. A census will be carried out prior to the start
of the study. LLIN distribution numbers will be calcu-
lated based on data from the census. Consent for the
house modifications will be obtained from individual
homeowners during door-to-door visits, following the
randomization of villages to trial arms.
Each candidate village is associated with a health center
that is responsible for providing medical care to a group
of villages. In cases where the health center is not situated
in the village, a Community Health Worker (CHW) is
charged with providing routine care for uncomplicated
malaria, diarrhea, and mild respiratory infections in chil-
dren. Study team members will visit each of the health
centers associated with a trial village, to inform the health
center officials of the trial activities. CHWs in the trial
villages will be trained in the trial procedures.
Eligible children will be randomly selected for recruit-
ment into the active case detection (ACD) cohort in
each village. Recruitment will be limited to children aged
eight or younger, to avoid children aging out during the
two year monitoring period. Study team members will
seek informed consent from the parents or caregivers of
the children before enrolling the child in the cohort.
Children aged eight will be asked to assent, in addition
to parental consent. Children in the treatment arm will
be recruited for the cohort irrespective of whether they
live in a house that has been modified with SET to avoid
bias related to house structure.
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Study design
The study design is summarized in Fig. 2 and a schedule
of trial activities is presented in Table 1. The design is a
two-armed CRT with 20 villages (clusters) per arm.
Villages will be allocated to an arm through restricted
randomization. Villages in the control arm will receive
universal coverage of LLINs, while the villages in the treat-
ment arm will receive universal coverage of LLINs and
heads of household living in suitable houses will also be of-
fered the SET intervention free of charge. The target cover-
age for SET in the treatment arm is ≥65% of all houses in
the village. After the installation of SET (in the treatment
arm) and the distribution of LLINs (in both arms), the
epidemiological and entomological monitoring will begin.
During the first visit and one year after recruitment, all
children in the ACD cohort will be cleared of malarial par-
asites. Children in the cohort will be monitored for two
years to determine clinical malaria incidence, malaria
infection incidence, and prevalence of acute respiratory
infections. Twice a year, at the start and end of the rainy
season, all children in the cohort aged five years or youn-
ger will be tested for anemia. If the child leaves the village
permanently or the parents withdraw their consent, an-
other child will be recruited into the cohort, preferably of
similar age and in the same household.
Indoor mosquito density will be monitored every other
month in 12 randomly selected houses in each village
using CDC light traps. Indoor and outdoor mosquito
density and exposure to infectious bites will be assessed
using human landing catches (HLC) every month in four
randomly selected houses per village. Four villages in
each study arm will be selected for insecticide resistance
monitoring. The villages will be selected based on the
presence of permanent breeding sites. Mosquitoes from
these eight villages will be sampled once a year over four
years (once before the start of the study, once each year
of the study, and once after the end of the study).
Questionnaires will be administered to consenting par-
ticipants in six study villages (three in each trial arm) at
the start and end of the monitoring period, and in two
study villages (one in each trial arm) at the midpoint of
the monitoring period. Ethnographic studies will take
place in three of the villages in the trial arm during the
installation of the SET intervention. Focus groups also
will be conducted midway through the trial in two
villages from the treatment arm and one village from the
control arm. Data from the social science activities will
inform the economic evaluation, but no primary cost
data will be collected from households.
Randomization and blinding
Allocation of villages to study arms will be restricted to
randomizations that limit the difference between the
mean values in each study arm of the following: malaria
prevalence; socioeconomic status; village size, and
proportion of houses suitable for SET. Data on these
variables by cluster will be obtained through a pre-trial
cross-sectional survey. Data on any additional potentially
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Fig. 1 Map of study area and 40 candidate study villages
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confounding ecological factors not included in the
randomization will be collected and corrected for in the
analysis.
Given the nature of the intervention, it is impossible to
conduct this study in a fully blinded manner but those
parts of the data collection that can be blinded will be.
Observer bias will be reduced where feasible. All labora-
tory work with samples will be blinded where possible.
Standard light traps that do not rely on the ability of the
fieldworker to collect specimens will be used to reduce
mosquito collector bias, in addition to HLCs. All analyses
will be conducted on blinded data.
Interventions
The SET intervention consists of four elements:
1. House modification. Any open eaves or gaps in the
walls will be sealed with concrete. Windows will be
screened and damaged doors will be repaired with
wood.
2. Eaves tube installation. A 20 cm long piece of PVC
pipe with a diameter of 15 cm (the eave tube) will
be installed at 1.5 - 2 m intervals into the outer
walls of occupied rooms (e.g. bedrooms and living
rooms but not storage rooms). The target location
will be approximately 20 cm below the roof, but
this may need to be adapted depending on different
house designs.
3. Maintenance. The condition of the SET
intervention will be monitored through village
‘walk-throughs’ every two months, when any
damage to window screening, eave tubes, doors, or
walls will be recorded and repaired.
4. Insecticide treatment and retreatment. The eave
tube inserts will be treated using a commercially
available, 10% wettable powder formulation of the
pyrethroid insecticide beta-cyfluthrin (Tempo Ultra
WP, Bayer). Inserts in the study will be replaced
with freshly treated inserts if bioassay mortality falls
below 70%.
Persistence of the insecticide will be monitored by
monthly bioassays with local, field-collected mosquitoes.
These bioassays will consist of an eave tube with the
Fig. 2 Summary of study design
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insert placed at the end of the tube. A bottle filled with
hot water and covered with a worn sock will be placed be-
hind the insert to act as a host cue. Local, field-collected
2–5 day old female An. gambiae s.l. mosquitoes will be
allowed to recruit freely to the insert for one hour and
knock down and mortality will be assessed 24 h post
exposure.
LLINs (Permanet 2.0; Vestergaard Frandsen, Switzerland)
will be distributed at universal coverage to each household
in all of the study villages. Côte d’Ivoire’s national malaria
control program (NMCP) guidelines will be followed to en-
courage consistent and correct use of the LLINs. During
the routine visits to villages for epidemiological and ento-
mological monitoring, trial staff will administer standard-
ized questionnaires, including questions on the presence of
LLINs in the sleeping areas and their use by the household.
Epidemiological evaluations
Children enrolled in the ACD cohort will receive routine
visits from the study team (a trained nurse and the
Table 1 Timetable of trial activities
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CHW) every two weeks (rainy season) or every month
(dry season).
At the first visit, additional data will be collected on
household level socioeconomic indicators, methods of
vector control used in the household, and sleeping habits.
Children five years of age or younger will have a blood
sample taken for immediate measurement of hemoglobin
levels using a spectrophotometer (HemoCue Hb 201+,
Radiometer Medical Aps, Ängelholm, Sweden). All chil-
dren will receive a three-day course of a first-line antimal-
arial recommended by the NMCP in Côte d’Ivoire
(artesunate-amodiaquine or artemether-lumefantrine), to
clear any existing malaria parasite infection. The study
team will observe adherence for the first dose and parents
or guardians will be instructed to complete the treatment
at home. The CHW will be instructed to check compli-
ance and the parents or guardians will be asked to bring
the empty drug packet to the following visit. A thick blood
smear will be taken on the next visit (two weeks later) to
confirm parasite clearance.
At all visits, the child’s axillary temperature will be re-
corded. If the child is febrile (axillary temperature ≥
37.5 °C), or has a history of fever in the past 48 h, or if
the parents report that the child is sick, a health exam
will be carried out and a record will be made of the
child’s symptoms, pulse, and respiratory rate. A blood
sample will be taken from febrile children by finger prick
for a malaria rapid diagnostic test (mRDT; SD Bioline
Malaria Ag P.f./Pan, Standard Diagnostics, Inc., Gyeonggi,
Republic of Korea). A thick blood smear and a blood spot
on filter paper will also be taken for subsequent confirm-
ation of the infection. If the mRDT is positive and the
study nurse diagnoses uncomplicated malaria, the child
will be treated with a first-line antimalarial (artesunate-a-
modiaquine) for three days, according to the guidelines of
the NMCP. Treatment for malaria will be provided free of
charge through this system. If the child exhibits any symp-
toms of severe illness, he or she will be sent immediately
to the closest health clinic for treatment. Once a month, a
thick blood smear and blood spot will be taken from all
children in the cohort to monitor for asymptomatic para-
site infections. During these visits, a record will be made
of recent travel, and whether the child slept under an
LLIN the preceding night.
Four times during the course of the monitoring period,
at the start and end of the rainy season, all children in the
cohort will be checked for respiratory symptoms (cough,
nasal discharge, rales, elevated age specific respiratory
rate, and chest indrawing) and children five years of age or
younger will have a blood sample taken for immediate
measurement of hemoglobin levels using a spectropho-
tometer. One year after the initial parasite clearance, at
the start of the next rainy season, all of the cohort children
will again be cleared of malaria parasites with a three-day
course of front-line antimalarials (artesunate-amodia-
quine), confirmed by thick blood smear on the following
visit.
To capture any malaria cases that occur between cohort
visits, the parents or guardians will be given a card at the
initial visit, identifying the child as a participant in the
study, with instructions to present this card whenever the
child receives medical treatment between visits. The back
of the trial card will provide space to record the date of
visit and the diagnosis.
Entomological evaluations
Each month, mosquitoes will be sampled using human
landing catches (HLC) both indoors and outdoors for
one night at four randomly selected houses in each of
the 40 study villages. Starting at 18:00, one capturer will
sit inside of the house in the living room area and one
will sit outside of the house. These capturers will collect
mosquitoes on their bare feet and legs using small glass
tubes, which will then be plugged with cotton and
brought back to the laboratory. A supervisor will pass by
every hour to ensure that the capturer is awake and fol-
lowing the correct capture protocol. At 01:00, a second
team will take over and continue the captures until
08:00. When the HLC samples are brought back to the
lab, the mosquitoes will be identified using a species key
based on morphological traits [28]. A subset of the
captured An. gambiae s.l. and all An. funestus and An.
nili females will be dissected to determine parity. Both
species are known to be vectors of malaria in Côte
d’Ivoire [29–31], however An. gambiae s.l. is the numeric-
ally dominant vector in the trial area [32]. After dissection,
mosquitoes will be preserved for later PCR analysis to de-
termine sporozoite prevalence. PCR will also be used to
type An. gambiae s.l. females to species, and to measure
the prevalence of kdr and ace-1 resistance mutations.
In addition to the HLC sampling, CDC light traps will
be placed every other month in 12 randomly selected
houses for one night in each village. These traps will be
set in the sleeping area at 18:00 and removed the following
morning at 08:00. The study team members will record
the number of people who slept in the room during the
trap night, the number of LLINs installed in the sleeping
area, and whether the people reported sleeping under the
available LLINs during the trap night. The mosquitoes
captured in the traps will be brought back to the labora-
tory for morphological species identification.
To monitor resistance in the study area throughout
the course of the trial, larval dips will be used to collect
An. gambiae larvae from eight study villages (four per
arm). These field-collected larvae will be reared to
adulthood in the insectary at IPR, and bioassays will be
conducted with 2–5 day old females. WHO insecticide
susceptibility bioassays will be conducted using diagnostic
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concentrations of the active ingredient in the LLINs
(deltamethrin) and the eave tubes (beta-cyflutherin).
CDC bottle bioassays will also be done with both
actives, to measure resistance intensity. A susceptible
An. gambiae lab strain (Kisumu) will be tested as a con-
trol in these bioassays. After the bioassays, surviving
mosquitoes will be put in RNAlater and stored at -80 °C
for subsequent microarray analysis to monitor expression
of genes potentially involved in metabolic resistance.
Social science
During the trial, data will be collected on perceptions of
and willingness to adopt the SET intervention, know-
ledge relating to the SET intervention, and attitudes and
emotions relating to malaria and new malaria prevention
interventions. These data will be collected using three
complimentary methodologies: (1) questionnaires ad-
ministered to homeowners and heads of household, (2)
ethnographic studies (observation and informal discus-
sion), and (3) focus groups.
The questionnaires will be administered before the in-
stallation of the intervention and at the end of the moni-
toring period in the six villages designated for social
science activities (see [33] for more details on the method-
ology for these activities). Questionnaires will also be
administered in two of the villages midway through the
monitoring period. The ethnographic studies will be
conducted during and directly after the SET installation
process, and during the installation of insecticide treated
inserts in three villages in the SET arm. Focus group dis-
cussions will be held midway through the monitoring
period with people drawn from diverse demographic
groups (mothers, village leaders, young adults) in two SET
+ LLIN villages and one LLIN village.
Economics
Data on the incremental financial and economic costs of
SET will be collected alongside the intervention and
attributed to either housing modification (screening,
closing eaves), eaves tube installation, SET maintenance,
or treatment and retreatment of inserts with insecticide.
Where resources (e.g. staff ) are shared between more
than one element, costs will be allocated using a suitable
proxy. Costs for research activities will be excluded. Fi-
nancial costs will be obtained from project expenditure
records. Economic costs (including financial expenditure
and donated resources) will be identified from project
records and via social science activities, with a value for
donated resources being imputed from market rates.
Capital costs will be annualized over their useful life
(financial costing) and annualized at a discount rate of
3% in the economic costing.
The numbers of malaria cases averted in the SET +
LLIN arm compared to the LLIN only arm will be used
to calculate disability adjusted life years (DALYs) averted
using standard methods [34]. If the epidemiological data
suggest an effect on anemia and/or respiratory infections,
this will also be included in the DALY calculations.
Trial oversight
A Trial Steering Committee (TSC) will be established to
provide oversight of the study. TSC members will be
independent of the trial and its institutions, and have
the necessary expertise to monitor study progress and
participant safety. The TSC will be responsible for moni-
toring the progress of the trial, adherence to protocol,
patient safety, and for consideration of new information.
The TSC will also have access to the study data at regu-
lar intervals to determine if additional interim analyses
of trial data should be undertaken, and assess any safety
issues that may arise during the study. The TSC can
make the decision to stop the study at any point.
Day-to-day management of the trial is the responsibility
of the chief investigator and co-investigators. They will
maintain appropriate medical and research records, in
compliance with Good Clinical Practice (GCP), and all
regulatory and institutional requirements. Standard Oper-
ating Procedures (SOPs) will be developed in accordance
with Good Clinical Practice (GCP) and Good Field Ento-
mology Practice (GFEP). An independent consultant will
review study protocols, SOPs, and QA reports. A study
monitor will conduct audits at key phases of the study.
Safety considerations
The LLINs distributed as part of this trial (Permanet 2.0)
have been fully evaluated by the WHO Pesticide Evalu-
ation Scheme (WHOPES) and are routinely distributed
by the NMCP in Côte d’Ivoire.
The beta-cyfluthrin used on the eave tube inserts is a
pyrethroid insecticide, which typically have low mamma-
lian toxicity and good safety profiles. The trial will use a
commercially available formulation of the insecticide. The
inserts will be machine treated to minimize contact with
the insecticide dust. All personnel responsible for treating
and installing treated inserts will be provided with the
appropriate personal protective equipment (PPE).
In addition to safety considerations relating to the use of
insecticides, concerns have previously been raised with
regards to house modifications and the possibility that
they might increase risk of acute respiratory infections
due to changes in the indoor environment [12]. To moni-
tor for adverse events (AEs), regardless of whether they
are due to insecticide use or house modifications, children
enrolled in the ACD cohort will be monitored at each visit
for symptoms including skin irritation, respiratory prob-
lems, headaches, fatigue, and nausea. The nurses respon-
sible for the ACD visits will record these or any other
adverse events, and report them to their supervisor. AEs
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occurring in non-cohort children living in the study
villages will be recorded through passive monitoring of
visits to the local health facilities and the CHWs. If a par-
ent or guardian agrees to participate, a verbal autopsy
using an established questionnaire will be conducted after
any deaths in the cohort. The host institution (IPR)
medical expert and his clinical team will be responsible
for recording, reporting, and managing AEs and SAEs,
including follow-up, in accordance with national guide-
lines. A report on AEs and SAEs, including deaths in the
cohort, will be provided regularly to the TSC.
HLC capturers will be vaccinated against yellow fever
free of charge if they do not already have proof of yellow
fever vaccination. If they become sick with malaria at
any point during the trial, they will be provided treat-
ment free of charge at the nearest health facility.
Handling of drop-outs / withdrawals
Participants are free to withdraw from the study at any
point for any reason. Participants include children in the
ACD cohort, households where entomological monitoring
is conducted, and capturers conducting HLCs. For chil-
dren in the ACD cohort, the reason for premature termin-
ation or withdrawal will be documented – e.g., SAE,
withdrawal of consent, loss to follow up. If the child with-
draws from the cohort for any of these reasons, another
child will be selected to replace them, preferably in the
same age group and from the same household but if that
is not possible, then from another randomly selected
household.
Study endpoints
Epidemiological
The primary endpoint of the trial will be the incidence of
clinical malaria determined by active case detection in
children six months to ten years of age. Clinical malaria
will be defined as an axillary temperature of ≥37.5 °C
combined with a positive mRDT. The secondary clinical
endpoints will be: (1) incidence of asymptomatic malaria
infection detected by microscopy and/or PCR, (2) preva-
lence of anemia in children five years of age or younger
(measured four times during the study), and (3) incidence
of the following symptoms of respiratory infection: cough,
nasal discharge, rales, elevated age specific respiratory
rate, and chest indrawing.
Entomological
The primary entomological endpoints will be the mean
number of malaria vectors (An. gambiae s.l., An. funes-
tus, and An. nili) captured per person per night both in-
doors and outdoors by HLC, and the mean number of
malaria vectors captured indoors per trap per night by
CDC light trap. The secondary endpoints will be: (a) the
entomological inoculation rate (EIR) for An. gambiae
s.l., An. funestus, and An. nili calculated as the mean
number of sporozoite infective bites/person/year, (b)
parity of An. gambiae s.l., An. funestus, and An. nili, (c)
the prevalence (% mortality using a diagnostic dose) and
strength (LD50 and resistance ratios) of insecticide re-
sistance to deltamethrin and beta-cyfluthrin measured
before, during, and after the trial period in An. gambiae
s.l.
Social science
The social science endpoints will be the percentage of
homeowners who consent to the SET intervention when
offered, and the degree to which consent can be
predicted based on psychosocial predictors. In addition,
observations and discussions on attitudes towards the
technology will be considered in anticipation of diffusion
and scale up of the technology to other communities.
Economics
The economic endpoints will be marginal economic and
financial cost per malaria case averted and the cost per
DALY averted of the SET intervention compared to
LLINs alone.
Sample size rationale
Epidemiological
The epidemiological impact of SET alone or in combin-
ation with LLINs is currently unknown. A minimum ef-
fect size of 40% was used in the sample size calculations,
which is similar to the effect size used in other sample
size calculations for house-based malaria interventions
[12, 35]. The mean incidence of clinical malaria in the
reference arm was assumed to be 0.5 malaria cases per
child per year, based on existing data from the study
area. Further assuming a coefficient of variation (k) of
0.5, (a conservative estimate for a high transmission set-
ting), 80% power and significance level of 5%, requires
20 clusters per arm and 50 children per cluster to be
followed for two years (encompassing 2 peak transmis-
sion seasons).
Entomological
Pilot studies in semi-field systems in Tanzania and Kenya
suggest an up to 80% reduction in mosquito entry into
houses with eave tubes and screening [20, 21]; a more
conservative 50% reduction was used for these sample size
calculations. Again, this is consistent with other RCTs
testing the effect of house modifications on entomological
endpoints [12, 13]. A baseline survey conducted during
the dry season in the study area had mean HLC catches of
23.5 An. gambiae/trap/night, with SD = 17 and intraclass
correlation (ICC) = 0.84. For 80% power to detect a 50%
drop in mean mosquito densities of 23 mosquitoes at the
5% significant level, 7 households need to be sampled in
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each of the 40 villages. To capture the substantial seasonal
changes and to accommodate available resources, 4 ran-
domly selected households will be sampled over one night
in each village every month, powered to detect a differ-
ence for every two months of pooled data.
CDC light traps consistently caught fewer mosquitoes
than the HLC during the baseline survey, with a mean
nightly catch of 2.5 An. gambiae, a log SD of 1.7 and
ICC = 0.229. To detect a 50% reduction mosquito dens-
ity with 80% power at the 5% significance level requires
12 households per cluster. In order to capture seasonal
variation in mosquito density, collections will be per-
formed every two months.
Data management
Clinical data will be collected by study nurses on Android
tablets using standardized data entry forms in the Open
Data Kit (ODK) Collect app and sent directly to a secure
electronic server. Routine data checks will be performed
to identify incomplete, missing, inaccurate, or inconsistent
data, which will be rectified by the appropriate supervisor.
Field workers will not have access to the data once it has
been collected. Children in the ACD cohorts will be
assigned a unique code, which will be used as an anonym-
ous identifier in the datasets and to label clinical samples.
Access to the data will be password protected and re-
stricted to only authorized study investigators and data
management staff. Any hardcopy documents will be
stored in locked filing cabinets and accessible only to
authorized study personnel. Documents will be held for at
least five years at the host institution (IPR).
Statistical analysis
Epidemiological
Protective efficacy against clinical malaria and malaria
infection will be determined by comparing incidence
rates of malaria infection and clinical malaria between
arms. Following any treatment for malaria, a child will
not be considered at risk for four weeks and this period
will therefore be censored from follow-up. Overnight
stays outside of the village will be recorded with a short
questionnaire administered during the cohort visits. If
travel outside of the village is common, it will be in-
cluded as a covariate in the analysis.
Primary intention to treat analysis will be comparison of
the incidence of clinical malaria episodes in the two inter-
vention groups. All analysis will use a mixed effects model
to test the difference in incidence rate between the two
arms, allowing for repeated measurements on the same
individual, and within-cluster correlation of responses.
The effect of year and possible confounders such as age of
child, gender, antimalarial drug use, baseline infection
status, etc. will be analyzed in separate as per protocol
analysis.
Survival analysis will be used to compare time to first
infections, adjusting for confounding factors using a Cox
proportional hazards model, again using methods that
allow for within-village correlation of responses.
Entomological
Differences in mean mosquito density (for indoor and
outdoor catches) between the two study arms will be
analyzed using Poisson regression or negative binomial
models, accounting for within-village correlation of re-
sponses. Sporozoite rates will be compared between the
two arms and between indoor and outdoor caught mos-
quitoes, using logistic regression models. EIR will be cal-
culated for each study night and compared between study
arms using negative binomial regression.
Social science
Pre-intervention willingness to adopt the SET interven-
tion will be compared to actual consent by logistic re-
gressions. The predictors of willingness to adopt will be
tested with structural equation modeling. Profiles of
perceptions of the SET intervention will be identified
using latent class analysis. Ethnographic and focus group
information will be evaluated using thematic analysis.
Economics
The economic and financial cost of the SET intervention
will be presented as total and disaggregated by program
element to illustrate the relative share of each element
to program costs. Costs will also be presented according
to cost categories (e.g. labor, insecticide) to illustrate cost
drivers. Costs will be converted into cost per house and
cost per person receiving the intervention per year, to
facilitate comparison with other malaria vector control
interventions (e.g. IRS). Alternative program scenarios
(e.g. different scale, duration and insecticide treatment
frequency) will be presented to estimate operational
implementation costs. Uncertainty and sensitivity analysis
will be conducted.
The numbers of malaria cases averted in the SET +
LLIN arm, compared to the LLIN only arm, will be used
to calculate disability adjusted life years (DALYs) averted
using standard methods [34]. If the epidemiological data
suggest an effect on anemia or respiratory infections,
this will also be included in the DALY calculations. To-
gether with cost data, DALY estimates will be used to
compare SET with other potential malaria interventions
using evidence from the literature.
Interim analysis
An interim analysis of malaria incidence and transmis-
sion potential will be done after one year of monitoring.
The purpose of the interim analysis is to inform plan-
ning of future trials. The current protocol will remain
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unchanged regardless of interim results. The funder will
not have access to any data, only summary results.
P-values will be adjusted appropriately in the final ana-
lysis to account for the interim analysis.
Discussion
Past success in reducing the global malaria burden has
highlighted both the importance of vector control in
preventing transmission, and the challenges that remain
in meeting the targets set out by the WHO Global Tech-
nical Strategy (GTS) for Malaria 2016–2030 [3]. IRS
coverage has declined to just 2.9% of people at risk for
malaria worldwide, likely due to the increased cost asso-
ciated with switching away from pyrethroid insecticides
in response to widespread pyrethroid resistance in vector
populations [8]. This leaves the majority of malaria vec-
tor control dependent on LLINs. While LLIN coverage
has increased over time, there are still concerns over op-
erational limits on increasing coverage and use [36, 37]
and insecticide resistance in vector populations [38, 39].
Even maintaining current levels of LLIN coverage might
be insufficient to prevent a resurgence in case incidence,
as immunity wanes in populations following LLIN distri-
bution campaigns [40]. Thus, there is a strong argument
to be made that meeting the GTS milestones will require
a greater diversity of vector control tools than currently
exist [4, 5].
The aim of this CRT is to evaluate whether SET pro-
vides additional protection against malaria, compared to
LLINs alone. Based on previous house improvement tri-
als [11, 13, 14], “mosquito proofing” of houses (screening
windows, sealing cracks and open eaves) is expected to
reduce the number of infective bites received indoors
and, consequently, reduce malaria incidence in members
of households with the SET intervention. It is also
possible that the insecticide component of the SET
intervention could have an additional effect on malaria
incidence in the SET villages, by killing mosquitoes that
attempt to enter houses such that infective bites are
reduced even in unmodified houses [19, 41]. However,
the trial is not explicitly designed to disaggregate the
protection provided by the house modifications and the
protection provided by the insecticide.
The decision was made to use a pyrethroid insecticide
for this CRT, despite intense pyrethroid resistance in the
study area. The rationale for this decision was two-fold:
first, pyrethroids are a relatively safe class of insecticides
with low mammalian toxicity and second, of all the
candidate actives evaluated in preliminary testing, the
beta-cyfluthrin formulation had the highest bioassay
mortality for the longest period of time when tested with
local, field collected, pyrethroid resistant mosquitoes
(Oumbouke, unpublished observations). The efficacy of
a pyrethroid against resistant mosquitoes is not surprising,
given that the delivery method (i.e. a powder formulation
Fig. 3 Examples of ventilation bricks commonly found in the study area in central Côte d’Ivoire. These are often either left unscreened, or
blocked (e.g. with LLINs, as shown in the top left image)
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on electrostatic netting) has previously been shown to be
effective against resistant mosquitoes [23]. Although a
pyrethroid is being used for the current CRT, this study
partly serves as a proof of concept for the SET interven-
tion as a delivery mechanism. If it is effective, SET could
potentially be implemented with a variety of other active
ingredients and formulations, including non-pyrethroid
insecticides and even biological actives such as entomo-
pathogenic fungi [42, 43].
Given that SET requires permanent modifications to
the house structure, both cost and user acceptability
are a concern. Several social science and economic
activities have been planned in parallel with the epi-
demiological and entomological monitoring to address
these issues. One specific concern is that closing open
eaves could reduce airflow within the house, which
could alter indoor temperature and humidity, and thus
negatively impact the comfort of those living in the
house. It is worth noting that the majority of houses in
this area already have closed eaves, in many cases with
ventilation holes built in at eave level (Fig. 3), similar to
eave tubes. However, there are regional differences in
housing design, and the feasibility and acceptability of
the SET intervention is likely to depend on local
context, which will require further studies with the
technology.
If the SET intervention is effective at reducing mal-
aria, acceptable to the local population, and
cost-effective as a malaria prevention intervention, the
question becomes how to implement the intervention at
scale. It has been argued that house improvements on
their own will likely have to be implemented outside of
the existing health sector, which provides funding for
LLIN distributions and IRS campaigns [12]. However, in
addition to house improvements, the SET intervention
includes a mosquito-killing device in the eave tube,
which could provide one avenue for a more typical,
donor-funded distribution model. This does not have to
be the only model, but rather one of a suite of imple-
mentation strategies. This CRT serves as a first, essen-
tial step in demonstrating the epidemiological and
entomological impact of the SET intervention, and esti-
mating acceptability and cost-effectiveness to inform
whether it is indeed a viable malaria control strategy
that should be implemented at scale.
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